Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALMS Alumis Inc.

Pre-Mkt 10-26 09:04:13 EDT

6.78

-0.04

-0.59%

盘前6.95

+0.17+2.51%

07:39 EDT

High6.83	Low6.48	Vol1.23M
Open6.68	D1 Closing6.82	Amplitude5.05%
Mkt Cap874.62M	Tradable Cap619.31M	Total Shares129.00M
T/O8.27M	T/O Rate1.35%	Tradable Shares91.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ALMS","market":"US","secType":"STK","nameCN":"Alumis Inc.","latestPrice":6.78,"timestamp":1792785600000,"preClose":6.82,"halted":0,"volume":1230177,"hourTrading":{"tag":"盘前","latestPrice":6.95,"preClose":6.78,"latestTime":"07:39 EDT","volume":6,"amount":41.1506022,"timestamp":1793014768892,"change":0.17,"changeRate":0.025074,"amplitude":0.019174},"delay":0,"changeRate":-0.005865102639296193,"floatShares":91343700,"shares":129000000,"eps":-3.800544,"marketStatus":"Pre-Mkt","change":-0.04,"latestTime":"10-26 09:04:13 EDT","open":6.68,"high":6.825,"low":6.4804,"amount":8268503.8146672,"amplitude":0.050528,"askPrice":7.04,"askSize":79,"bidPrice":6.24,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.800544,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1793021400000},"marketStatusCode":1,"adr":0,"listingDate":1719547200000,"exchange":"NASDAQ","adjPreClose":6.78,"preHourTrading":{"tag":"盘前","latestPrice":6.95,"preClose":6.78,"latestTime":"07:39 EDT","volume":6,"amount":41.1506022,"timestamp":1793014768892,"change":0.17,"changeRate":0.025074,"amplitude":0.019174},"postHourTrading":{"tag":"盘后","latestPrice":6.78,"preClose":6.78,"latestTime":"19:30 EDT","volume":44774,"amount":303568.4822,"timestamp":1792798204780,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7456331278905611,"impliedVol":0.6885,"impliedVolPercentile":0.096},"requestUrl":"/m/hq/s/ALMS/wiki","defaultTab":"wiki","newsList":[{"id":"2674855343","title":"Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2674855343","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674855343?lang=en_us&edition=fundamental","pubTime":"2026-10-09 18:37","pubTimestamp":1791542233,"startTime":"0","endTime":"0","summary":"BRIEF-Alumis Says Envudeucitinib Improves Psoriasis Symptoms in Phase 3 DataOct 9 (Reuters)-Alumis Inc.ALMS.O:ALUMIS ANNOUNCES NEW PHASE 3 DATA DEMONSTRATING ENVUDEUCITINIB RAPIDLY AND DURABLY IMPROVE","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUAT99LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674834309","title":"Alumis Says Phase 3 Data Show Envudeucitinib Delivers 54% PASI 100 Response at Week 48 in Psoriasis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674834309","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674834309?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:00","pubTimestamp":1791532855,"startTime":"0","endTime":"0","summary":"Alumis says Phase 3 data show envudeucitinib delivers 54% PASI 100 response at Week 48 in psoriasis trialAlumis released new Phase 3 psoriasis data presented at the 26th Annual Fall Clinical Dermatolo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nNDLbR8xxg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","ALMS","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","SG9999014039.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","BK4007","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674834553","title":"Alumis - over 80% of Onward3 Patients Maintain Clear or Almost Clear Scalp Skin at 48 Weeks","url":"https://stock-news.laohu8.com/highlight/detail?id=2674834553","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674834553?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:00","pubTimestamp":1791532800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUAT99LG:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674783439","title":"Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2674783439","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674783439?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:00","pubTimestamp":1791532800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUAT99LG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674683455","title":"Alumis - Plans Nda Submission for Envudeucitinib in 4Q 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674683455","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674683455?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:00","pubTimestamp":1791532800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUAT99LG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674555834","title":"Alumis - Onward3 Shows 54% Pasi 100 Skin Clearance at Week 48 for Envudeucitinib","url":"https://stock-news.laohu8.com/highlight/detail?id=2674555834","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674555834?lang=en_us&edition=fundamental","pubTime":"2026-10-09 16:00","pubTimestamp":1791532800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261009:nTUAT99LG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673704851","title":"Alumis Initiated With Buy on TYK2 Opportunity; Envu’s Strong Psoriasis Profile Supports Unchanged $15 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2673704851","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673704851?lang=en_us&edition=fundamental","pubTime":"2026-10-05 18:56","pubTimestamp":1791197760,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Alumis Inc. today and set a price target of $15.00. Mitchell Kapoor has given hi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/alumis-initiated-with-buy-on-tyk2-opportunity-envus-strong-psoriasis-profile-supports-unchanged-15-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/alumis-initiated-with-buy-on-tyk2-opportunity-envus-strong-psoriasis-profile-supports-unchanged-15-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560995","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560995?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:10","pubTimestamp":1789038656,"startTime":"0","endTime":"0","summary":"Aeon Biopharma  shares were up more than 39% in Thursday's premarket activity after the company announced positive data from a pilot forced degradation study for its lead drug candidate, ABP-450.Culp  stock was 19% higher after the company swung to fiscal Q1 earnings and higher revenue.Golden Heaven Group  shares up were more than 15% after a 4.3% rise in the prior session.Vince  stock was 11% higher after the company's Q2 results.Alumis  shares were up more than 6%, swinging from a 7.4% fall at the previous close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4202","AEON","BK4216","BK4139","BK4007","ALMS","VNCE","GDHG","BK4010","CULP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666559445","title":"Alumis Director Srinivas Akkaraju Reports Disposal of 96,131 Common Shares Worth $1.01 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2666559445","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666559445?lang=en_us&edition=fundamental","pubTime":"2026-09-10 09:40","pubTimestamp":1789004425,"startTime":"0","endTime":"0","summary":"Alumis director Srinivas Akkaraju reports disposal of 96,131 common shares worth $1.01 millionDirector Srinivas Akkaraju reported net purchases of Alumis common stock through affiliated funds in early","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nNDLbwXXZK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alumis Director Srinivas Akkaraju Reports Disposal of 96,131 Common Shares Worth $1.01 Million","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666532362","title":"Wells Fargo Sticks to Its Buy Rating for Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666532362","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666532362?lang=en_us&edition=fundamental","pubTime":"2026-09-10 01:15","pubTimestamp":1788974122,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Derek Archila maintained a Buy rating on Alumis Inc. today and set a price target of $25.00. Archila covers the Healthcare sect...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","PGF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664691331","title":"Alumis to Present at Wells Fargo Annual Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664691331","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664691331?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:01","pubTimestamp":1788523291,"startTime":"0","endTime":"0","summary":"Alumis to present at Wells Fargo annual healthcare investor conferenceAlumis will join investor conferences in September 2026, including Wells Fargo in Boston on Sept. 8-10.Management is scheduled for","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDLbt0W1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0557290698.USD","LU1244550494.USD","IE00BN0W2W23.USD","SG9999014005.SGD","KBWB","BK4534","LU0106831901.USD","LU0225283273.USD","IE00B64PRP62.GBP","ALMS","LU1064131342.USD","IAI","LU1244550577.SGD","LU1668664300.SGD","BCDF","LU2210150020.SGD","LU1720051017.SGD","BK4585","IE00BKVL7J92.USD","LU1720051108.HKD","LU2089284900.SGD","BK4127","LU1791710582.SGD","LU2111349929.HKD","LU2028103732.USD","LU0106261372.USD","LU0320765646.SGD","BK4504","SG9999014039.USD","LU0971096721.USD","SG9999014013.SGD","LU1732800096.USD","LU0795875169.SGD","LU0158827948.USD","LU0314104364.USD","LU2357305700.SGD","LU1989772840.SGD","LU0098860793.USD","LU2133065610.SGD","LU1548497426.USD","NDAQ","LU1162221912.USD","LU2089283258.USD","LU0267386448.USD","SG9999014021.USD","LU2487616109.SGD","LU2347655156.SGD","LU1074936037.SGD","BK4588","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808827","title":"Analysts’ Top Healthcare Picks: uniQure (QURE), Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808827?lang=en_us&edition=fundamental","pubTime":"2026-09-03 22:30","pubTimestamp":1788445821,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on uniQure (QURE), Alumis Inc. (ALMS) and Omnicell (OMC...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-uniqure-qure-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-uniqure-qure-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LABU","BK4581","XBI","HCSG","BK4585","BK4588","LU0029874061.USD","LU0320765992.SGD","BK4137","LU0128526141.USD","QURE","XLV","BK4139","ALMS","LU0109394709.USD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664728877","title":"Alumis Cut to Neutral from Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2664728877","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664728877?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:46","pubTimestamp":1788443160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664636879","title":"Guggenheim Downgrades Alumis to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2664636879","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664636879?lang=en_us&edition=fundamental","pubTime":"2026-09-03 19:15","pubTimestamp":1788434106,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) has an average rating of buy and mean price target of $31.44, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and re","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664873762","title":"Alumis downgraded to Neutral from Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2664873762","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664873762?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:40","pubTimestamp":1788428413,"startTime":"0","endTime":"0","summary":"Guggenheim downgraded Alumis (ALMS) to Neutral from Buy without a price target after the Phase IIb study evaluating envudeucitinib in systemic lupu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-downgraded-to-neutral-from-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664730678","title":"Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST) and Alumis Inc. (ALMS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664730678","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664730678?lang=en_us&edition=fundamental","pubTime":"2026-09-03 17:40","pubTimestamp":1788428406,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Envista Holdings (NVST) and Alumis Inc. (ALMS). En...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-envista-holdings-nvst-and-alumis-inc-alms-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0034390439.USD","BK4007","LU0130518102.USD","HCSG","LU0477156797.USD","LU0128526141.USD","LU1201861165.SGD","LU0029874061.USD","XBI","LU0130103400.USD","BK4137","ALMS","BK4581","NVST","BK4585","IE00B19Z6F94.USD","XLV","BK4588","BK4082","LABU","LU0648000940.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664311845","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2664311845","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664311845?lang=en_us&edition=fundamental","pubTime":"2026-09-03 01:50","pubTimestamp":1788371420,"startTime":"0","endTime":"0","summary":"Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a \"Notice of Allowance\" for a patent application covering tri-specific antibody constructs and methods of use, f","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4140","LHSW","PPBT","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664884843","title":"Alumis rises 10.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664884843","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664884843?lang=en_us&edition=fundamental","pubTime":"2026-09-03 00:05","pubTimestamp":1788365143,"startTime":"0","endTime":"0","summary":"Alumis (ALMS) is up 10.7%, or $1.01 to $10.48. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alumis-rises-10-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alumis-rises-10-7-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664284869","title":"Alumis' Share Price Fall After Envudeucitinib Trial Data Likely Overreaction, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2664284869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664284869?lang=en_us&edition=fundamental","pubTime":"2026-09-02 23:40","pubTimestamp":1788363637,"startTime":"0","endTime":"0","summary":"Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitinib to treat systemic lupus erythematosus was likely an overreaction, Oppenheimer said in a note email","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ALMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664816199","title":"Alumis Price Target Cut to $15.00/Share from $25.00 by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2664816199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664816199?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:30","pubTimestamp":1788348600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ALMS/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALMS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alumis.com","stockEarnings":[{"period":"1week","weight":0.1078},{"period":"1month","weight":-0.0887},{"period":"3month","weight":-0.7579},{"period":"6month","weight":-0.728},{"period":"1year","weight":0.4707},{"period":"ytd","weight":-0.3053}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Alumis Inc. was incorporated on January 29, 2021, as a Delaware corporation. It is a clinical-stage biopharmaceutical company initially focused on developing two tyrosine kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor designed to achieve maximal target inhibition, and A-005, a CNS-penetrant molecule. The company's mission is to significantly improve patients' lives by replacing broad immunosuppression with targeted therapies.","exchange":"NASDAQ","name":"Alumis Inc.","nameEN":"Alumis Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Alumis Inc.,ALMS,Alumis Inc.股票,Alumis Inc.股票老虎,Alumis Inc.股票老虎国际,Alumis Inc.行情,Alumis Inc.股票行情,Alumis Inc.股价,Alumis Inc.股市,Alumis Inc.股票价格,Alumis Inc.股票交易,Alumis Inc.股票购买,Alumis Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Alumis Inc.(ALMS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Alumis Inc.(ALMS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}